Ant venom immunotherapy in Australia: The unmet need

Medical Journal of Australia

Volumn 201, Issue 1, 2014, Pages 33-34

  Mullins, Raymond J ^a   Brown, Simon G A ^b,c  

^a John James Medical Centre   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANT VENOM; BEE VENOM; IMMUNOLOGICAL ADJUVANT;

ALLERGIC REACTION; ANAPHYLAXIS; ANT; ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG RESEARCH; EMERGENCY WARD; FUNDING; HOSPITAL SERVICE; HUMAN; IMMUNOTHERAPY; INSECT STING; JACK JUMPER ANT; NONHUMAN; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEADY STATE; TREATMENT TOLERABILITY;

ANAPHYLAXIS; ANT VENOMS; AUSTRALIA; DESENSITIZATION, IMMUNOLOGIC; EVIDENCE-BASED MEDICINE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; HYPERSENSITIVITY; RISK FACTORS;

EID: 84904508309     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.00035     Document Type: Article

References (13)

1. Brown SGA, Franks RW, Baldo BA, Heddle RJ. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. J Allergy Clin Immunol 2003; 111: 187-192.
2. Douglas RG, Weiner JM, Abramson MJ, O'Hehir RE. Prevalence of severe ant-venom allergy in southeastern Australia. J Allergy Clin Immunol 1998; 101 (1 Pt 1): 129-131.
3. Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114: 371-376.
4. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009; 123: 434-442.
5. Brown SGA, van Eeden P, Wiese MD, et al. Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study. Med J Aust 2011; 195: 69-73.
6. Clarke PS. The natural history of sensitivity to jack jumper ants (Hymenoptera formicidae Myrmecia pilosula) in Tasmania. Med J Aust 1986; 145: 564-566.
7. Brown SGA, Wu QX, Kelsall GR, et al. Fatal anaphylaxis following jack jumper ant sting in southern Tasmania. Med J Aust 2001; 175: 644-647.
8. Weiner JM, Baldo BA, Donovan GR, Sutherland SK. Allergy to jumper ant (Myrmecia pilosula) stings in south-eastern Australia. Ann Allergy Asthma Immunol 1995; 74: 60.
9. Ruëff F, Biló MB, Cichocka-Jarosz E, et al. Immunotherapy for hymenoptera venom allergy: too expensive for European health care? Allergy 2013; 68: 407-408.
10. Oude Elberink JN, van der Heide S, Guyatt GH, Dubois AE. Immunotherapy improves health-related quality of life of adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy 2009; 39: 883-889.
11. Brown SGA, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003; 361: 1001-1006.
12. Brown SGA, Wiese MD, van Eeden P, et al. Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. J Allergy Clin Immunol 2012; 130: 162-168.
13. Australasian Society for Clinical Immunology and Allergy. Position statement: jack jumper ant venom immunotherapy. 2013. http://www. allergy.org.au/health-professionals/papers/jack-jumper-ant-venomimmunotherapy (accessed Oct 2013).